The clinical spectrum of aspergillosis in chronic obstructive pulmonary disease.

"Declarations Conflict of interestDenning and family hold Founder shares in F2G Ltd, a University of Manchester spin-out antifungal discovery company. He acts, or has recently acted, as a consultant to Pulmatrix, Pulmocide, Zambon, iCo Therapeutics, Mayne Pharma, Biosergen, Bright Angel Therapeutics, Cipla and Metis. He sits on the DSMB for a SARS CoV2 vaccine trial. In the last three years, he has been paid for talks on behalf of Dynamiker, Hikma, Gilead, Merck, Mylan and Pfizer. The other co-authors have no conflict of interest to declare. Ethical approvalNot applicable. Conflict of interest Denning and family hold Founder shares in F2G Ltd, a University of Manchester spin-out antifungal discovery company. He acts, or has recently acted, as a consultant to Pulmatrix, Pulmocide, Zambon, iCo Therapeutics, Mayne Pharma, Biosergen, Bright Angel Therapeutics, Cipla and Metis. He sits on the DSMB for a SARS CoV2 vaccine trial. In the last three years, he has been paid for talks on behalf of Dynamiker, Hikma, Gilead, Merck, Mylan and Pfizer. The other co-authors have no conflict of interest to declare."

"Funding No funding was received for this article."